94 results about "Cetuximab" patented technology

The invention discloses a transgenic T cell of a targeted CD30 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding the targeted CD30 antigen, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell containing a recombinant lentivirus expression vector (including a gene which is shown as SEQ ID NO:2 and encodes the targeted CD30 antigen and shRNA of a targeted PD1 gene or / and shRNA of a targeted CTLA4 gene); the primary cell is CD4+T cell or CD8+T cell. A preparation method comprises the following steps: firstly, carryingout lentivirus infection on the CD4+T cell or the CD8+T cell; secondly, mixing gRNA, CRISPR-cas9mRNA and HDR, and carrying out electroporation recombination on the T cell to obtain a finished product.According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are knocked out or silenced, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

The present disclosure relates to bispecific antibodies targeting EGFR and HER2, and methods for the production of these antibodies. The bispecific antibodies consist of one complete antibody on whichtwo VH-VL chains are attached via a linker to each NH terminal region of both VH chains of the antibody. The bispecific antibodies constructed use the amino acid sequences of the heavy chain (VH) andthe light chain (VL) variable regions of two monoclonal antibodies targeting EGFR and HER2, namely cetuximab and trastuzumab, respectively

The invention provides compositions and methods for determining the likelihood of successful treatment with Cetuximab or other equivalent. The methods comprise determining the genomic polymorphism present in a predetermined region of the FcγRIIa gene at amino acid position 131 and / or alternatively the FcγRIIIa gene at amino acid position 158.

In one aspect, the disclosure relates to antibodies with altered glycosylation patterns, methods of production of said antibodies, and methods of use thereof. In some embodiments, the antibody is cetuximab.

The invention discloses a transgenic T cell of a targeted CD19 antigen. The transgenic T cell is a primary cell which is integrated with a gene shown as SEQ ID NO:8 and encoding the targeted CD19 antigen in chromosome, and knocks out a PD1 gene and / or CTLA4 gene, or is a primary cell which is integrated with a gene shown as SEQ ID NO:2 and encoding a targeted PSA-NCAM receptor ,and a gene shown asSEQ ID NO:8 and encoding the targeted CD19 antigen in the chromosome; the primary cell is CD4+T cell or CD8+T cell. The invention also discloses application of the transgenic T cell of the targeted CD19 antigen in preparation of a medicine for treating malignant B cell lymphoma. According to the transgenic T cell disclosed by the invention, a recognition sequence of an EGFR (Epidermal Growth Factor Receptor) is introduced in carT construction; if necessary, a carT cell can be eliminated by using EGFR monoclonal antibody Cetuximab, the PD1 gene and the CTLA4 gene are silenced or knocked out, inhibition of the gene to the carT cell is eliminated, and the function of overcoming a tumor microenvironment and inhibiting immune cells by the carT cell are enhanced.

The invention provides compositions and methods for determining the likelihood of successful treatment with Cetuximab or other equivalent. The methods comprise determining the genomic polymorphism present in a predetermined region of the FcγRIIa gene at amino acid position 131 and / or alternatively the FcγRIIIa gene at amino acid position 158.

The invention discloses an anti-EGFR (epidemic growth factor receptor) humanized antibody L2-H3 and a coding gene and application thereof. The antibody is formed by a light chain and a heavy chain, wherein the heavy chain is formed by connection of a heavy chain variable region and a heavy chain constant region; the amino acid sequence of the heavy chain variable region is shown in the 1st-145th positions in the SEQ ID NO:3; the heavy chain constant region is the heavy chain constant region of a humanized antibody IgG1; and the amino acid sequence of the light chain is shown in the SEQ ID NO:1. The experimental results prove that the antibody has good binding activity and capability of inhibiting growth and migration of the tumor cells; and the affinity of the common anti-EGFR human-mouthchimeric antibody, namely cetuximab in the domestic and foreign markets is 1.1*10<9>M. The humanized antibody disclosed by the invention can better bind with the EGFR, thus ensuring the anti-tumor effect of the humanized antibody. By adopting a method for preparing the antibody, the light chain and the heavy chain can be simultaneously expressed, the expression ratio of the light chain to the heavy chain is closer to 1:1, and the mutually matched double-chain antibody with higher ratio is generated. In conclusion, the antibody and the preparation method have broad application prospects in thefield of tumor prevention and / or treatment.

The invention discloses a human colorectal cancer cetuximab drug-resistant cell line, and belongs to the field of biomedical technology. The human colorectal cancer cetuximab drug-resistant cell linehas the advantages that a human colorectal cancer cell line NCI-H508 is treated by the cetuximab of different concentration, and the drug concentration for survival of 50% of cells is used as the initial concentration to treat the cells for a long time, until the cell NCI-H508 can normally grow under the concentration; the cell NCI-H508 is continued to treat for a long time by a gradual increasingmethod, the treatment duration is six months, and finally the human colorectal cancer cetuximab drug-resistant cell line NCI-H508 / C225 which can quickly grow under the treatment function of the cetuximab can be finally obtained; the human colorectal cancer cetuximab drug-resistant cell line can be used for analyzing the phenotypic change of morphology and biology after drug resistance of human colorectal cancer cetuximab, studying the molecule mechanism of the human colorectal cancer cetuximab drug resistance and the reversing drug resistance method, screening other anti-tumor drugs, findingthe tumor drug-resistant markers, and screening and evaluating the novel antitumor drugs and the like, and the scientific and research value and the production and application value are higher.

The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.